These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35394498)

  • 21. Delivering a Double Whammy: Targeting Stroma to Improve Immunotherapy Outcomes in Pancreatic Ductal Adenocarcinoma.
    Lavania S
    Gastroenterology; 2022 Nov; 163(5):1159-1161. PubMed ID: 36067817
    [No Abstract]   [Full Text] [Related]  

  • 22. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
    Blair AB; Zheng L
    Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.
    Ijichi H; Chytil A; Gorska AE; Aakre ME; Bierie B; Tada M; Mohri D; Miyabayashi K; Asaoka Y; Maeda S; Ikenoue T; Tateishi K; Wright CV; Koike K; Omata M; Moses HL
    J Clin Invest; 2011 Oct; 121(10):4106-17. PubMed ID: 21926469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.
    Tan E; El-Rayes B
    J Gastrointest Cancer; 2019 Mar; 50(1):1-8. PubMed ID: 30446922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exosomes and the Future of Immunotherapy in Pancreatic Cancer.
    Batista IA; Melo SA
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.
    Zhang L; Wang W; Wang R; Zhang N; Shang H; Bi Y; Chen D; Zhang C; Li L; Yin J; Zhang H; Cao Y
    Mol Ther; 2021 Feb; 29(2):744-761. PubMed ID: 33130310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer.
    Hegde S; Krisnawan VE; Herzog BH; Zuo C; Breden MA; Knolhoff BL; Hogg GD; Tang JP; Baer JM; Mpoy C; Lee KB; Alexander KA; Rogers BE; Murphy KM; Hawkins WG; Fields RC; DeSelm CJ; Schwarz JK; DeNardo DG
    Cancer Cell; 2020 Mar; 37(3):289-307.e9. PubMed ID: 32183949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreatic ductal carcinoma: from the bench to the bedside.
    Pezzilli R
    JOP; 2006 Sep; 7(5):508-10. PubMed ID: 16998251
    [No Abstract]   [Full Text] [Related]  

  • 30. Endoscopic ultrasound may be used to deliver gene expression signatures using digital mRNA detection methods to immunophenotype pancreatic ductal adenocarcinoma to facilitate personalized immunotherapy.
    Gleeson FC; Levy MJ; Jackson RA; Murphy SJ; Halling KC; Kipp BR; Graham RP; Zhang L
    Pancreatology; 2020 Mar; 20(2):229-238. PubMed ID: 31831392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes.
    Furukawa K; Tanemura M; Miyoshi E; Eguchi H; Nagano H; Matsunami K; Nagaoka S; Yamada D; Asaoka T; Noda T; Wada H; Kawamoto K; Goto K; Taniyama K; Mori M; Doki Y
    PLoS One; 2017; 12(10):e0184901. PubMed ID: 29077749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy.
    Oyama Y; Onishi H; Koga S; Murahashi M; Ichimiya S; Nakayama K; Fujimura A; Kawamoto M; Imaizumi A; Umebayashi M; Ohuchida K; Morisaki T; Nakamura M
    J Immunother; 2020 May; 43(4):121-133. PubMed ID: 31834207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disrupting the balance between tumor epithelia and stroma is a possible therapeutic approach for pancreatic cancer.
    Wang Z; Li J; Chen X; Duan W; Ma Q; Li X
    Med Sci Monit; 2014 Oct; 20():2002-6. PubMed ID: 25327552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Islets and pancreatic ductal adenocarcinoma - An opportunity for translational research from the 'Bench to the Bedside'.
    Barreto SG; Michael MZ; Keating DJ
    Pancreatology; 2020 Apr; 20(3):385-390. PubMed ID: 32057682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.
    Orth M; Metzger P; Gerum S; Mayerle J; Schneider G; Belka C; Schnurr M; Lauber K
    Radiat Oncol; 2019 Aug; 14(1):141. PubMed ID: 31395068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance.
    Beatty GL; Eghbali S; Kim R
    Am Soc Clin Oncol Educ Book; 2017; 37():267-278. PubMed ID: 28561678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction.
    Tanemura M; Miyoshi E; Nagano H; Eguchi H; Matsunami K; Taniyama K; Hatanaka N; Akamatsu H; Mori M; Doki Y
    World J Gastroenterol; 2015 Oct; 21(40):11396-410. PubMed ID: 26523105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma.
    Cinar P; Ko AH
    J Natl Compr Canc Netw; 2014 Feb; 12(2):167-72. PubMed ID: 24586078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia and pancreatic ductal adenocarcinoma.
    Yamasaki A; Yanai K; Onishi H
    Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is targeting autophagy a promising lead to unveil the cloak of invisibility in pancreatic cancer?
    Cayron C; Rigal S; Guillermet-Guibert J
    Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101622. PubMed ID: 33770630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.